EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group

Prog Clin Biol Res. 1989:303:111-6.

Authors

M Pavone-Macaluso¹, F H Schröder, H J de Voogt, G Viggiano, E Barasolo, B Lardennois, M de Pauw, R Sylvester, P H Smith, S Suciu

Affiliation

¹ Institute of Urology, University of Palermo, Italy.

PMID: 2528735

No abstract available

Publication types

Clinical Trial
Comparative Study
Multicenter Study
Randomized Controlled Trial

MeSH terms

Androgen Antagonists / therapeutic use*
Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
Cyproterone / analogs & derivatives*
Cyproterone / therapeutic use
Cyproterone Acetate
Diethylstilbestrol / therapeutic use*
Europe
Humans
Male
Medroxyprogesterone / analogs & derivatives*
Medroxyprogesterone / therapeutic use
Medroxyprogesterone Acetate
Multicenter Studies as Topic
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / pathology
Random Allocation

Substances

Androgen Antagonists
Antineoplastic Agents
Cyproterone Acetate
Diethylstilbestrol
Medroxyprogesterone Acetate
Cyproterone
Medroxyprogesterone